In an effort to fulfill his campaign promise of lowering drug prices, President Trump has recently struck a deal with pharmaceutical company AstraZeneca to reduce prices for certain medications under the Medicaid program.

The agreement, announced by the White House on Monday, aims to make prescription drugs more affordable for millions of Americans who rely on government-funded health insurance. AstraZeneca has agreed to lower the prices of several of its most popular drugs, including those used to treat conditions such as diabetes, asthma, and high blood pressure.

Under the terms of the deal, AstraZeneca will also provide rebates to the federal government for certain medications, further reducing the cost burden on taxpayers. The move comes as part of Trump's broader efforts to tackle rising healthcare costs and make prescription drugs more affordable for all Americans.

Critics of the deal have raised concerns about the impact on AstraZeneca's bottom line, but supporters argue that the move is a step in the right direction towards addressing the issue of skyrocketing drug prices in the United States. As the debate over healthcare reform continues, the deal between Trump and AstraZeneca marks a significant milestone in the push to lower prescription drug costs for American patients.